bioRxivMicrobiology
Phospholipid Metabolism Is Associated with HIV Rebound Upon Treatment Interruption
L. B. Giron, E. Papasavvas, X. Yin, A. Goldman, H.-Y. Tang, C. Palmer, A. L. Landay, J. Z. Li, J. Koethe, K. C. Mounzer, J. Kostman, Q. Liu, L. J. Montaner, M. Abdel-Mohsen
Abstract
Lipids are biologically active molecules involved in a variety of cellular processes and immunological functions, including inflammation. It was recently shown that phospholipids and their derivatives, lysophospholipids, can reactivate latent (dormant) tumor cells, causing cancer recurrence. However, the potential link between lipids and HIV latency, persistence, and viral rebound after cessation of antiretroviral therapy (ART) has never been investigated. We explored the links between plasma lipids and the burden of HIV during ART. We profiled the circulating lipidome from the plasma of 24 chronically HIV-infected individuals on suppressive ART who subsequently underwent an analytic treatment interruption (ATI) without concurrent immunotherapies. The pre-ATI viral burden was estimated as time-to-viral-rebound and viral load setpoints post-ATI. We found that higher pre-ATI levels of lysophospholipids, including the pro-inflammatory lysophosphatidylcholine, were associated with faster time-to-viral-rebound and higher viral setpoints upon ART cessation. Furthermore, higher pre-ATI levels of the pro-inflammatory byproduct of intestinal lysophosphatidylcholine metabolism, trimethylamine-N-oxide (TMAO), were also linked to faster viral rebound post-ART. Finally, pre-ATI levels of several phosphatidylcholine species (lysophosphatidylcholine precursors) correlated strongly with higher pre-ATI levels of HIV DNA in peripheral CD4+ T cells. Our proof-of-concept data point to phospholipids and lysophospholipids as plausible pro-inflammatory contributors to HIV persistence and rapid post-ART HIV rebound. The potential interplay between phospholipid metabolism and both the establishment and maintenance of HIV latent reservoirs during- and post-ART warrants further investigation. IMPORTANCEThe likelihood of HIV rebound after stopping antiretroviral therapy (ART) is a function of the interplay between the size of HIV reservoirs that persist despite ART and the host immunological and inflammatory factors that modulate these reservoirs. There is a need to comprehensively understand these host factors to develop a strategy to cure HIV infection and prevent viral rebound post-ART. Lipids are important biologically active molecules that are known to mediate several cellular functions, including reactivating latent tumor cells; however, their role in HIV latency, persistence, and post-ART rebound has never been investigated. We observed significant links between higher levels of the pro-inflammatory lysophosphatidylcholine and its intestinal metabolic byproduct, trimethylamine-N-oxide, and both faster time-to-viral rebound and higher viral load setpoint post ART. These data highlight the need for further studies to understand the potential contribution of phosphatidylcholine and lysophosphatidylcholine metabolism in shaping host immunological and inflammatory milieu during- and post-ART.
- organism: human
- assay: metabolomics
- research focus: host-pathogen & immune response
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Plasma metabolomics reveals lipid-predominant metabolic disruptions in virologically suppressed people with HIV
Christopher M. Basting, Candace Guerrero, … Nichole R. Klatt·bioRxiv·Aug 20, 2026
- Assessing The Impact Of Autologous Neutralizing Antibodies On Viral Rebound In Postnatally SHIV-Infected ART-Treated Infant Rhesus Macaques
E. Mainou, S. J. Berendam, … M. R. Kumar·bioRxiv·Jul 22, 2023
- Laboratory surrogate markers of residual HIV replication among distinct groups of individuals under antiretroviral therapy
R. S. Diaz, L. B. Giron, … M. C. Sucupira·bioRxiv·Sep 13, 2018
- Unique CD8+ T Cell Populations Expand during ART and Predict Delayed HIV-1 Rebound
Jie Wang, Gautam Kundu, … the RV254 study team·bioRxiv·Aug 18, 2026
- Ongoing lymphoid HIV production drives pyroptosis and GLP-1 counter-regulation in ART-suppressed infection
Peter A Crawford, Joshua Rhein, … Timothy W. Schacker·bioRxiv·Jan 10, 2026
- Therapeutic CD8+T cell tissue retention and immunomodulation during ART interruption fails to prevent SIV rebound
María Betina Pampena, Sadia Samer, … Michael R. Betts·Proceedings of the National Academy of SciencesPeer-reviewed·Aug 14, 2025